Caliper Life Sciences competitors

Mr. Norman D. Schwartz is Chairman of the Board, President, Chief Executive Officer of Bio Rad Laboratories Inc. Mr. Schwartz has been President and Chief Executive Officer since 2003 and Chairman of the Board since 2012. He was Vice President from 1989 to 2002, Group Manager, Life Science, from 1997 to 2002 and Group Manager, Clinical Diagnostics, from 1993 to 1997.

Francis Aurelio deSouza (born December 2, 1970) is an American entrepreneur and business executive. He is the president and chief executive officer (CEO) of Illumina and a member of the Board of Directors of The Walt Disney Company.

With a proven track record of bringing game-changing technologies to the market, Mr. Shamir joined Luminex Corporation as President, Chief Executive Officer, and Board Member in 2014. From 2006 to 2014, Mr. Shamir served as President and CEO of Given Imaging, a developer, manufacturer, and marketer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract, which was acquired by Covidien PLC in early 2014. Mr. Shamir currently serves on the board of directors of Exalenz Bioscience Ltd. (TASE: EXEN). He has previously served as a Board Member at Scitex Corporation, Cogentix Medical (NASDAQ: CGNT), recently acquired by Laborie Medical Technologies, and invendo medical GmBH, now part of Ambu. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University.

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Dr. Singh was elected President and Chief Executive Officer of PerkinElmer effective December 30, 2019, and appointed to our board of directors in August 2019. Previously Dr. Singh was the President and Chief Operating Officer of the Company since January 2019. Dr. Singh joined PerkinElmer as the President of our Diagnostics business in May 2014. He was elected Senior Vice President in September 2016 and Executive Vice President in March 2018. Prior to joining PerkinElmer, Dr. Singh was General Manager of GE Healthcare’s Women’s Health business from 2012 to 2014, with responsibility for its mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East region. Dr. Singh holds a doctoral degree in chemistry from the University of Missouri-Columbia and a Master of Business Administration from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals. Dr. Singh has more than twenty-five years of leadership experience with global innovators in healthcare technology. He has spent the most recent six years developing unique insights into both our business and our opportunities for continued growth. Dr. Singh brings to our board a detailed understanding of the core technologies that we utilize and the operational strategies available to us as we continue to focus on innovating for a healthier world.

Douglas C. Bryant became President and Chief Executive Officer on March 1, 2009. Prior to joining Quidel, Mr. Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations. From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr. Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa, and Vice President of Diagnostic Operations Asia Pacific. Mr. Bryant holds a B.A. in Economics from the University of California at Davis.

Speck Loe works at Medimmune and a Ceo at Medimmune and is based in Granite Falls, Washington.